莫蒂克萨福蒂德:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|November 23, 2023
概括
莫蒂克萨福蒂德是一种新型CXCR4抑制剂,已获批用于在多发性骨髓瘤患者中调动造血干细胞 (HSC). 这一里程碑标志着干细胞移植和癌症治疗的重大进展.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 莫蒂克萨福蒂德是一种选择性CXCR4抑制剂.
- 它是为血液造血干细胞 (HSC) 调动和癌症治疗而开发的.
研究的目的:
- 总结一下motixafortide的发展里程碑.
- 为了突出其最近的FDA批准用于多发性骨髓瘤中HSC调动.
主要方法:
- 对motixafortide的临床开发数据的审查.
- 对监管机构提交和批准的分析.
主要成果:
- 莫蒂克萨福蒂德于2023年9月11日在美国批准,与菲尔格拉斯蒂姆一起用于多发性骨髓瘤中HSC调动.
- 在胰腺癌和急性髓性白血病中获得孤儿药物指定.
结论:
- 莫蒂克萨福蒂德的批准代表了干细胞调动的重大进展.
- 目前正在进行的试验针对状细胞疾病的基因疗法,扩大其治疗潜力.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
188
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
188
Antidepressant Drugs: MAOIs and Other Agents
248
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
248


